A practical reference on HGF/c-Met: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-25 and is reviewed periodically as new material appears.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Provides straightforward information about effects arising from individual compounds in complex or natural samples separated in parallel. Combines chromatographic separation with effect-directed detection using enzymatic or biological assays. Helps to select important compounds from a sample for further characterization using high-resolution mass spectrometry. Offers unique benefits such as super-hyphenation, minimum sample preparation requirements, detection of multi-modulating compounds, and distinguishing agonistic versus antagonistic effects.
In order to locate Razzouki, we needed the same techniques that were used 30 years ago to track down Pablo Escobar, because Razzouki applied the same routines in order to stay under the radar and escape every surveillance by the Colombian authorities. Razzouki did not use any technology or social media for eight years, to the extent that he did not update his family in the Netherlands of any news. Our investigators tracked him down by using intelligence planes that regularly flew over the city of Medellín with the aim of locating him. The last time the Elite Colombian Police Unit intervened in such a case, was during the operation carried out on 2 December 1993 to track down and shoot Pablo Escobar. Razzouki is suspected of drug trafficking, manufacture and possession of illegal substances, homicide, and terrorism. He had changed his physical appearance with the help of cosmetic surgery in order to look older. Razzouki belonged to a European criminal organisation of the Moroccan Mafia and was at the head of a group of traffickers from the Clan del Golfo cartel who were involved in the international export of cocaine, especially to Spain and Portugal. The Iranian government allegedly protected Taghi as he worked together with the Iranian secret service, to assassinate enemies of the Iranian state who were hiding out on European soil. On 16 December 2019, Taghi was arrested in his mansion in Dubai after a manhunt by the Moroccan and European authorities, and three days later he was deported to the Netherlands.
A protein microarray (or protein chip) is a high-throughput method used to track the interactions and activities of proteins, and to determine their function, and determining function on a large scale. Its main advantage lies in the fact that large numbers of proteins can be tracked in parallel. The chip consists of a support surface such as a glass slide, nitrocellulose membrane, bead, or microtitre plate, to which an array of capture proteins is bound. Probe molecules, typically labeled with a fluorescent dye, are added to the array. Any reaction between the probe and the immobilised protein emits a fluorescent signal that is read by a laser scanner. Protein microarrays are rapid, automated, economical, and highly sensitive, consuming small quantities of samples and reagents. The concept and methodology of protein microarrays was first introduced and illustrated in antibody microarrays (also referred to as antibody matrix) in 1983 in a scientific publication and a series of patents. The high-throughput technology behind the protein microarray was relatively easy to develop since it is based on the technology developed for DNA microarrays, which have become the most widely used microarrays.
== Interactions == CNS depressants may enhance the depressant effects of hydromorphone, such as other opioids, anesthetics, sedatives, hypnotics, barbiturates, benzodiazepines, phenothiazines, chloral hydrate, dimenhydrinate, and glutethimide. The depressant effect of hydromorphone also may be enhanced by monoamine oxidase inhibitors (MAO inhibitors), first-generation antihistamines (e.g., brompheniramine, promethazine, diphenhydramine, chlorphenamine), beta blockers, and alcohol. When combined therapy is contemplated, the dose of one or both agents should be reduced.
Sources: en.wikipedia.org
In 2008, Air Chief Marshal Sir Glenn Torpy Head of the Royal Air Force, for his part in Operation Telic / Operation Iraqi Freedom. Lieutenant General Sir James Dutton, Royal Marines, "in recognition of meritorious, gallant and distinguished services during coalition operations in Afghanistan". Major General Colin Boag, British Army, "in recognition of gallant and distinguished services during coalition operations in Iraq" (March 2008). Lieutenant General James Bucknall, British Army, "in recognition of gallant and distinguished services during coalition operations in Iraq" (July 2009). Major General Mohamed Elkeshky, Egyptian Army Defense, Military, Naval and Air Attaché to the United States. (2013). In 2011, Vice Admiral Tomohisa Takei, Japan Maritime Self-Defense Force, "as recognition for Takei's exceptional leadership and expertise in maturing and expanding the JMSDF and U.S. Navy partnership during his role as director of operations and plans department, JMSDF Maritime Staff Office from April 2008 to July 2010". In 2013, Lieutenant General Walter Souza Braga Netto, Brazilian Army, Military Attaché to the United States of America. "For exceptionally meritous conduct in the performance of outstanding services from March 2011 to May 2013. In 2014, Air Commodore David Best, United Kingdom Royal Air Force. "For exceptionally meritorious service as Director of Air Operations, International Security Assistance Force, from December 2010 to December 2011". In 2014, Major General Brett Cairns, Canadian Air Force, NORAD J3.
== Career == After her PhD, Chutia continued her research at Dibrugarh University for another year as a CSIR-postdoctoral fellow. She entered the field of plasma physics at the Physical Research Laboratory in Ahmedabad and then joined the Institute for Plasma Research in Gandhinagar. She then returned to the Institute of Advanced Study in Science and Technology as a faculty member and set up the Plasma Physics Laboratory. After finishing a fellowship awarded by the Japanese government in 1988 to work at the Plasma Laboratory of the Institute of Space and Astronautical Science, Tokyo, in 2005 she became the director of the Institute of Advanced Study in Science and Technology.
=== Acquired and inherited enzyme deficiencies === Downregulation of kynurenine 3-monooxygenase (KMO) can be caused by genetic polymorphisms, cytokines, or both. KMO deficiency leads to an accumulation of kynurenine and to a shift within the tryptophan metabolic pathway towards kynurenic acid and anthranilic acid. Deficiencies of one or more enzymes on the kynurenine pathway leads to an accumulation of intermediate metabolic products which can cause effects depending on their concentration, function and their inter-relation with other metabolic products. For example, kynurenine 3-monooxygenase deficiency is associated with disorders of the brain (such as schizophrenia and tic disorders) and of the liver. The mechanism behind this observation is typically a blockade or bottleneck situation at one or more enzymes on the kynurenine pathway due to the effects of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) and/or due to genetic polymorphisms afflicting the particular genes. Dysfunctional states of distinct steps of the kynurenine pathway (such as kynurenine, kynurenic acid, quinolinic acid, anthranilic acid, 3-hydroxykynurenine) have been described for a number of disorders, for example:
Patrick Robert David Kearon (born 18 July 1961) is a British religious leader serving as a member of the Quorum of the Twelve Apostles of the Church of Jesus Christ of Latter-day Saints. He has been a general authority of the church since 2010 and was a member of the Presidency of the Seventy from August 2017 to December 2023. On 1 August 2020, Kearon became the senior president of the seventy, becoming the first in this role to have been born outside the United States since the reconstitution of the Presidency of the Seventy in 1975. As a member of the Quorum of the Twelve, Kearon is accepted by the church as a prophet, seer, and revelator. Currently, he is the thirteenth most senior apostle in the church.
Official website About Hooters – the Atlanta-based chain's information page Original Hooters – the Clearwater-based founders sub-chain Transfer of "Hooters" brand from Clearwater to Atlanta, a March 2001 article from Atlanta Business Chronicle Sexual Harassment Retaliation Lawsuit, from The Smoking Gun Fortune magazine feature on Hooters Hooters All Set to Open in Phuket Thailand
Sources: en.wikipedia.org
=== Neutral phase === If the temperature variation from climatology is within 0.5 °C (0.9 °F), ENSO conditions are described as neutral. Neutral conditions are the transition between warm and cold phases of ENSO. Sea surface temperatures (by definition), tropical precipitation, and wind patterns are near average conditions during this phase. Close to half of all years are within neutral periods. During the neutral ENSO phase, other climate anomalies/patterns such as the sign of the North Atlantic Oscillation or the Pacific–North American teleconnection pattern exert more influence.
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup A10 is part of the anatomical group A Alimentary tract and metabolism. Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QA10. National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version. A10AB01 Insulin (human) A10AB02 Insulin (beef) A10AB03 Insulin (pork) A10AB04 Insulin lispro A10AB05 Insulin aspart A10AB06 Insulin glulisine A10AB30 Combinations === A10AC Insulins and analogues for injection, intermediate-acting === A10AC01 Insulin (human) A10AC02 Insulin (beef) A10AC03 Insulin (pork) A10AC04 Insulin lispro A10AC30 Combinations
By continuously scanning a surface, such as tissue section, nano-DESI can be used for imaging. By carefully choosing the experimental conditions, such as the nano-DESI solvent, additives, and the ionization mode (positive or negative) we can map the distribution of a wide variety of complex molecules on different surfaces. A few examples to mention are proteins, lipids, small metabolites, drugs or even the distribution of endogenous alkali metals. Nano-DESI has been applied for localized analysis of complex molecules and imaging of tissue sections, microbial communities and environmental samples. By decreasing the inner diameter of the primary and secondary capillaries, spatial resolution can be decreased to 20x20 μm or even smaller facilitating the analysis of individual cells. This way even various proteoforms can be measured in single cells as well as global and spatial metabolomics.
== Plot == By the year 1992, humanity has colonized the Moon and psychic powers are common. The protagonist, Joe Chip, is a debt-ridden technician working for Runciter Associates, a "prudence organization" employing "inertials"—people with the ability to negate the powers of telepaths and "precogs"—to enforce the privacy of clients. The company is run by Glen Runciter, assisted by his deceased wife Ella who is kept in a state of "half-life", a form of cryonic suspension that allows the deceased limited consciousness and ability to communicate. While consulting with Ella, Runciter discovers that her consciousness is being invaded by another half-lifer named Jory Miller. When business magnate Stanton Mick hires Runciter Associates to secure his lunar facilities from alleged psychic intrusion, Runciter assembles a team of 11 of his best inertials, including recent hire Pat Conley, a mysterious girl with the unique psychic ability to undo events by changing the past. Runciter and Chip travel with the group to Stanton's Moon base, where they discover that the assignment is a trap, presumably set by the company's main adversary, Ray Hollis, who leads an organization of psychics. A bomb blast apparently kills Runciter without significantly harming the others. They rush back to Earth to place him into half-life, but they cannot establish contact with him so his body is set to be buried. From the moment of the explosion, the group begins to experience shifts in reality.
On 15 June, US vice president JD Vance announced that the memorandum was digitally signed by both countries the previous day. On 17 June, Trump and Iranian president Masoud Pezeshkian signed the Islamabad Memorandum to end the war, with Trump signing it during dinner with French president Emmanuel Macron at the Palace of Versailles after the G7 summit. On 18 June, Pakistan stated that the signing of the memorandum implies Tehran will reopen the Strait of Hormuz "instantly" and the American blockade will end "immediately." CENTCOM announced that it had removed the naval blockade. On 19 June, Trump announced a renewed ceasefire between Israel and Hezbollah in the 2026 Lebanon war, facilitated by the US, Qatar, and Iran. However, on 20 June, Hezbollah announced an attack on Israeli forces trying to capture Ali al-Taher in Nabatieh, while Israel continued to strike southern Lebanon.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.